Scientific Team-GOPATH
diagnostic services Pharma



Sarah Bacus, Ph.D., Director of Pharma Initiatives
 
Dr. Bacus has earned worldwide recognition as a leader in personalized medicine. She has more than 30 years of experience in basic and applied research in oncology drug development and diagnostics.
 
Prior to joining GoPath, Dr. Bacus acted as Senior Vice President and Head of Translational Research for American Molecular Laboratories, which was preceeded by other executive and chief scientific roles at other diagnostics firms. She has also founded and sold four successful companies that were all focused on diagnostic and pre-clinical work for personalized medicine in oncology. These companies revolutionized tissue imaging, accelerated approval of drugs such as lapatinib and helped establish novel treatment strategies in use today. She has noteworthy accomplishments in preclinical drug development, applied and basic oncology research, personalized medicine and development of diagnostics and biomarkers. She has written more than 120 peer reviewed papers and has held multiple worldwide patened biomarkers.
 
Dr. Bacus has held professorships at Duke University and the University of Illinois at Chicago.  She earned a BSc in Physics and Mathematics, M.Sc. in Biophysics and a PhD in Medical Physics at the Hebrew University in Israel.

 
Christopher Hamm, Ph.D., Deputy Director of Pharma Initiatives
 
Dr. Hamm came to GoPath’s PharmaTargetTM team with strong academic credentials and valuable experience in the life sciences/biotechnology sector including human disease studies and therapeutic/drug pipeline/molecular diagnostic/clinical trial analyses. His expertise in the fields of cancer biology, immuno-oncology, molecular biology, cell biology, genetics, genomics, epigenetics and epigenomics gives him valuable insight when creating strategies in drug development.
 
Dr. Hamm is a proven project leader directly involved with the design and execution of basic and translational research projects with the goal of identifying novel therapeutics and companion diagnostics. His direct involvement with biotechnology/pharmaceutical companies includes evaluating products/pipelines, and identifying both key value drivers and undervalued investment opportunities. His doctoral background, combined with ongoing financial training, provides the biomedical expertise and investment knowledge that is directly relevant to modern scientific research (translational and clinical), biotechnology investment research, and strategic management consulting.
 
Prior to joining GoPath, Dr. Hamm acted as the Associate Director of Translational Research for American Molecular Laboratories where he helped develop genomic and proteomic immuno-oncology assays. Dr. Hamm has also acted as a project manager fand clinical genomics scientist for pharmaceutical and clinical research companies. He received his Ph.D. in Genetics from the University of Iowa. 


Zhongmin Guo, M.D., Ph.D., Director of Molecular Diagnostics and Development

Dr. Guo joined GoPath Laboratories as the Director of Molecular Diagnostics and Development in 2012. He oversees the operations of the Molecular Diagnostic Laboratory and office functions. Dr. Guo manages workflow, maintains CAP policies and procedures and heads all laboratory molecular diagnostic activities including new assay development, test validation and technical troubleshooting. Dr. Guo received his medical degree from Guangdong Medical College in China and received his Ph.D. in molecular biology and cancer biology from Uppsala University School of Medicine in Sweden. Soon after earning his Ph.D., Dr. Guo began his post-doc fellowship training in the Department of Otolarynology Head and Neck Cancer Research Center at Johns Hopkins University School of Medicine with a special focus on cancer genetics, epigenetics and cancer translational research. He also has had an extensive independent research career at both the University of Maryland School of Medicine and the Indiana University School of Medicine. Dr. Guo has more than 15 years of experience in clinical and academic laboratories and he brings a unique area of expertise in molecular biology and molecular genetics of human diseases to GoPath Laboratories.


Dr. Xiaolin Hu, Senior Scientist for Molecular Diagnostics & Development

Dr. Hu has a MBBS degree (equivalent to M.D.) from Anhui Medical University in China and a Ph.D. in Biochemistry and Molecular Biology from the Medical College of Georgia in Augusta, Georgia. Her main focus is acting as a project leader for the creation and development of diagnostic tests for cancer. She is mainly responsible for designing a validation plan, evaluating test protocols and quality controls in test development. She is also responsible for writing research proposals, SOPs, and study reports for relevant projects. Dr. Hu is also involved in providing training and technical support to fellow molecular personnel.


Hala Boulos, Staff Scientist

Ms. Boulos received her Master’s Degree in Biology with a focus on Molecular Genetics from Loyola University Chicago. She has 15 years of experience in research in pharmaco-, cancer & clinical genetics and has written a number of publications for those fields. She contributed greatly to the design and development of cancer & prenatal diagnostic products that are currently on the market in the US & Europe. Her focus at GoPath is on the advancement of new DNA-based diagnostic products for cancer genetics and oncogenesis.


David Sobczak, MS, MB (ASCPTM), Staff Scientist

Mr. Sobczak works under the guidance of the Director of Molecular Diagnosis and Development to lead the Clinical Molecular Diagnostics team in processing patient samples. He is also part of the Molecular Development team. Mr. Sobczak brings a strong technical proficiency to GoPath, primarily by focusing on next-generation sequencing. After earning his Master’s degree with specialization in molecular biology and cell physiology, David has had more than nine years of bench work experience in DNA, RNA, and protein analysis.